Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Hyku is a biotech company that develops precise covalent targeting of disease-causing proteins.
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
FundaMental Pharma is a neuroscience company with a portfolio at the preclinical stage.
Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.
Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington's disease.
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors.
A UK-based developer of drugs to treat respiratory diseases
Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.
Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
Kedalion Therapeutics is a biotechnology company that develops and commercializes transformative topical ophthalmic therapies.
Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Adicet Bio is a biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell therapies for cancer
Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.
IKAS Industrial Automation is provides intelligent manufacturing solutions for IC manufacturing and packaging testing, LED, photovoltaic.
Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.
Tagworks Pharmaceuticals is a privately held biotech company
Amphista Therapeutics operates as a biopharmaceutical company.
Soteria is a biotechnology company that develops immunotherapies to treat cancer patients
Arctos Medical is a developed gene therapy that does not correct rare genetic eye diseases but much more common cases of blindness.
Forendo Pharma is a developer of novel drugs intended for the treatment of urological and other endocrinological diseases.
Novartis Venture Fund has invested in 37 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novartis Venture Fund's top investment sectors include Biotechnology, Health Care, Therapeutics, Biopharma, Medical. The firm invests across 18 different industry categories.
Among tracked funding rounds, GentiBio received $157.0M in a Series A round. Novartis Venture Fund's total known invested capital is $1.8B.
Novartis Venture Fund's average investment size is $50.8M across its portfolio of 37 companies.
Recent Novartis Venture Fund portfolio additions include Renovacor, Hyku, GentiBio, FundaMental Pharma, Granite Bio. These companies were founded in 2020 or later.